These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21178719)

  • 21. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.
    Munfus-McCray D; Cui M; Zhang Z; Gabrielson E; Askin F; Li QK
    Hum Pathol; 2013 Jul; 44(7):1286-92. PubMed ID: 23337026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
    Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.
    Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Oncol Rep; 2007 Sep; 18(3):623-8. PubMed ID: 17671710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas.
    Alexander RE; Lopez-Beltran A; Montironi R; MacLennan GT; Post KM; Bilbo SA; Jones TD; Huang W; Rao Q; Sen JD; Meehan K; Cornwell A; Miravalle L; Cheng L
    Histopathology; 2012 Dec; 61(6):1036-42. PubMed ID: 22804747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
    Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
    Girard N; Deshpande C; Azzoli CG; Rusch VW; Travis WD; Ladanyi M; Pao W
    Chest; 2010 Jan; 137(1):46-52. PubMed ID: 19376842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR and KRAS mutations in metastatic lung adenocarcinomas.
    Munfus-McCray D; Harada S; Adams C; Askin F; Clark D; Gabrielson E; Li QK
    Hum Pathol; 2011 Oct; 42(10):1447-53. PubMed ID: 21497370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
    Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular analysis of liquid cytological samples collected by bronchoscopy with radial endobronchial ultrasonography and guide sheath.
    Iwabu N; Izumo T; Nakamura Y; Chavez C; Tsuchida T; Sasada S
    Ann Thorac Cardiovasc Surg; 2014; 20 Suppl():692-6. PubMed ID: 24747549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias.
    Kohno T; Kunitoh H; Suzuki K; Yamamoto S; Kuchiba A; Matsuno Y; Yanagitani N; Yokota J
    Carcinogenesis; 2008 May; 29(5):957-63. PubMed ID: 18299280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical and molecular characterization of clear cell carcinoma of the lung.
    Yousem SA
    Hum Pathol; 2013 Nov; 44(11):2467-74. PubMed ID: 24029707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
    Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
    Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
    Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
    J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.